Pharmaceutical industry expands manufacturing and clinical trial technologies

The pharmaceutical and biotechnology sectors are seeing significant operational and structural shifts. Bio-Techne has opened a new 10,000-square-foot GMP-grade small-molecule manufacturing facility in Bristol to support cell therapy developers moving toward clinical and commercial stages.

In the CDMO space, Symbiosis has expanded its commercial team with three new appointments to drive growth across the Asia-Pacific, Middle East, and Southern Europe markets. Meanwhile, the industry is addressing new challenges posed by prediction markets, such as Kalshi, which have highlighted the need for updated confidentiality language in vendor contracts to prevent data gaps between sponsors and external partners.

Technological advancements continue to influence clinical development, with discussions focusing on how AI can improve trial design, automate data transfer, and make patient enrollment more predictable. Additionally, the Pharma Times has relaunched its bi-monthly e-magazine to provide context on regulatory, technological, and market changes affecting the global healthcare landscape.